Ardelyx Inc (ARDX)
6.415
+0.10
(+1.66%)
USD |
NASDAQ |
Apr 26, 16:00
6.415
0.00 (0.00%)
After-Hours: 20:00
Ardelyx Free Cash Flow: -90.06M for Dec. 31, 2023
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| December 31, 2023 | -90.06M |
| September 30, 2023 | -67.02M |
| June 30, 2023 | -70.78M |
| March 31, 2023 | -87.23M |
| December 31, 2022 | -70.04M |
| September 30, 2022 | -123.70M |
| June 30, 2022 | -133.31M |
| March 31, 2022 | -137.04M |
| December 31, 2021 | -154.42M |
| September 30, 2021 | -132.88M |
| June 30, 2021 | -117.78M |
| March 31, 2021 | -101.78M |
| December 31, 2020 | -81.76M |
| September 30, 2020 | -75.06M |
| June 30, 2020 | -75.86M |
| March 31, 2020 | -84.70M |
| December 31, 2019 | -76.81M |
| September 30, 2019 | -84.40M |
| June 30, 2019 | -90.66M |
| March 31, 2019 | -80.80M |
| December 31, 2018 | -70.58M |
| Date | Value |
|---|---|
| September 30, 2018 | -47.19M |
| June 30, 2018 | -39.86M |
| March 31, 2018 | -46.52M |
| December 31, 2017 | -67.54M |
| September 30, 2017 | -101.72M |
| June 30, 2017 | -108.31M |
| March 31, 2017 | -108.83M |
| December 31, 2016 | -97.40M |
| September 30, 2016 | -89.95M |
| June 30, 2016 | -76.18M |
| March 31, 2016 | -82.48M |
| December 31, 2015 | -75.29M |
| September 30, 2015 | -58.06M |
| June 30, 2015 | -51.35M |
| March 31, 2015 | 3.491M |
| December 31, 2014 | 11.54M |
| September 30, 2014 | 27.27M |
| June 30, 2014 | 32.82M |
| March 31, 2014 | 4.514M |
| December 31, 2013 | 1.533M |
Free Cash Flow Range, Past 5 Years
-154.42M
Minimum
Dec 2021
-67.02M
Maximum
Sep 2023
-97.65M
Average
-87.23M
Median
Mar 2023
Free Cash Flow Benchmarks
| Nektar Therapeutics | -193.47M |
| Omeros Corp | 74.30M |
| Vistagen Therapeutics Inc | -26.12M |
| Karyopharm Therapeutics Inc | -92.72M |
| Adverum Biotechnologies Inc | -91.71M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -8.718M |
| Cash from Investing (Quarterly) | -29.57M |
| Cash from Financing (Quarterly) | 25.99M |
| Free Cash Flow Per Share (Quarterly) | -0.0377 |
| Free Cash Flow to Equity (Quarterly) | -31.35M |
| Free Cash Flow to Firm (Quarterly) | -5.923M |
| Free Cash Flow Yield | -6.37% |